Income Statement
The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Price to FCFE (P/FCFE)
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Abbott Laboratories, consolidated income statement
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Net sales | Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. | Abbott Laboratories net sales decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level. |
| Operating earnings | The net result for the period of deducting operating expenses from operating revenues. | Abbott Laboratories operating earnings decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
| Earnings from continuing operations before taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Abbott Laboratories earnings from continuing operations before taxes decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
| Net earnings | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Abbott Laboratories net earnings decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |